Please login to the form below

Not currently logged in
Email:
Password:

PCSK9

This page shows the latest PCSK9 news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Amgen offers Repatha deals in Europe, will Persephone slash Herceptin use?

Daily Brief: Amgen offers Repatha deals in Europe, will Persephone slash Herceptin use?

This puts it ahead of its fellow PCSK9 product and rival, however Sanofi and Regeneron unveiled strong strong cardiovascular outcomes data from their ODYSSEY trial in combination with the huge cut ... However, the majority of patients in Europe who could

Latest news

  • Esperion craters as deaths mar atherosclerosis drug study Esperion craters as deaths mar atherosclerosis drug study

    Esperion is hoping to position bempedoic as a once-daily, oral alternative to PCSK9 inhibitor such as Amgen’s Repatha (evolocumab) and Sanofi/Regeneron’s Praluent (alirocumab), which are given by ... Esperion recently reported phase II data showing

  • Segmentation, evolved Segmentation, evolved

    Along with results from its Odyssey Outcomes trial, Sanofi said that it plans to offer discounts of up to 69% to encourage payers to expand the use of the PCSK9 inhibitor. ... Research by Amgen, which has a PCSK9 called Repatha, suggests that two-thirds

  • Sanofi, Regeneron offer price cut for cholesterol drug Praluent Sanofi, Regeneron offer price cut for cholesterol drug Praluent

    The offer has been made just after the presentation of the large-scale ODYSSEY OUTCOMES at the American College of Cardiology (ACC) meeting in Orlando, which showed that adding PCSK9 inhibitor ... Both Praluent and Amgen’s rival PCSK9 inhibitor Repatha

  • After some big setbacks, Sanofi talks up its R&D portfolio After some big setbacks, Sanofi talks up its R&D portfolio

    The latter shift was made apparent when Sanofi and Regeneron said earlier this year they intend to end their ten-year-old alliance - which has delivered marketed products including anti-PCSK9

  • Amgen gets prevention claim for cholesterol drug Repatha Amgen gets prevention claim for cholesterol drug Repatha

    The new label gives Amgen a promotional edge for Repatha (evolcoumab) over rival PCSK9 inhibitor Praluent (alirocumab) from Sanofi and Regeneron as it tries to rev up sales of its product, ... their ability to sell the PCSK9 inhibitor in the US market.

More from news
Approximately 16 fully matching, plus 62 partially matching documents found.

Latest Intelligence

  • Astellas: Ten years young Astellas: Ten years young

    With the partners gearing up to launch Amgen's PCSK9 therapy for hypercholesterolemia - a class of drugs that is top of many peoples' minds - it's an approach that seems to

  • Pharma deals in September 2015 Pharma deals in September 2015

    Amgen's busy month (part 2). Following FDA approval for its novel PCSK9 treatment for “ bad cholesterol”, Amgen is moving onto tackle dyslipidemia, an asymptomatic disease in which serum lipid levels

  • Going the distance Going the distance

    Looking to the second half of this year and Sanofi is aiming for a Q3 launch for its new PCSK9 cardiovascular disease management drug Praluent (alirocumab), which comes from its collaboration

  • Pharma deals during November 2014 Pharma deals during November 2014

    In July, BioMarin sold its PRV to Regeneron for $68m to expedite filing of its cholesterol drug, the PCSK9 inhibitor alirocumab, being developed in partnership with Sanofi.

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Quintiles

With a network of more than 27,000 employees conducting business in approximately 100 countries, we have helped develop or commercialize...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics